Optometry & Visual Performance 154 Volume 14 | Issue 2 | June 2026 Article • Digital Therapies for Amblyopia Man Kin (Eric) Chow • Miami, Florida ABSTRACT Amblyopia is a developmental visual disorder with consequences beyond reduced visual acuity, affecting stereoacuity, contrast sensitivity, oculomotor function, and eye-hand coordination. While patching remains the longstanding standard of care, adherence challenges and its inherently monocular approach have driven the development of a new generation of digital and perceptual learning-based therapies. This article reviews five clinically relevant technologies— Luminopia, CureSight, Eye Hero, Bynocs, and RevitalVision—examining their mechanisms of action, treatment protocols, and supporting clinical evidence. Collectively, these platforms represent a meaningful expansion of the amblyopia treatment toolbox, offering patients and clinicians options that are engaging, home-based, and in many cases, capable of addressing the binocular and cortical deficits that patching alone does not target. Selecting the right tool requires an understanding of each platform’s unique delivery, its evidence base, and the patient’s individual visual profile. Keywords: amblyopia, dichoptic therapy, perceptual learning, digital therapeutics Introduction Amblyopia is a developmental visual disorder resulting from atypical binocular experience in early childhood, leading to abnormal visual cortex development and vision impairment. Recovery relies on neuroplasticity in the visual cortex.1 While reduced visual acuity is the hallmark most clinicians recognize, amblyopia’s impact extends far beyond the size of a letter on the eye chart. Affected individuals demonstrate deficits in contrast sensitivity, stereoacuity, spatial localization, spatial resolution, oculomotor function (including pursuits, saccades, and fixation stability), accommodation, vergence, suppression patterns, eye-hand coordination, motion perception, and temporal processing.2,3 For decades, the primary evidence-based treatment has been patching. The landmark PEDIG Amblyopia Treatment Studies, published over twenty years ago in 2003, established the foundational dosing parameters still used today: ATS 2A demonstrated that 6 hours per day of patching was equally effective as full-time patching for severe amblyopia, and ATS 2B showed that 2 hours per day was equally effective as 6 hours for mild to moderate amblyopia. These findings were groundbreaking at the time and remain clinically relevant, but they also define the lower bound of what we ask of our patients: a minimum of 2 hours per day with a patch over a child’s eye. Anyone who has treated amblyopia with patching knows the main obstacle isn’t the prescription, it is compliance. Adherence to patching has been reported to be between 40 and 60% by week 6 and may fall to approximately 30% by week 12.4 A treatment that children resist wearing, that carries social stigma, and that doesn’t quite address the binocular nature of the condition leaves room for improvement. The good news is that the gap is being filled. A new generation of digital and perceptual learningbased therapies is reshaping how we approach amblyopia treatment. In this article, I will review five clinically relevant emerging technologies— Luminopia, CureSight, Eye Hero, Bynocs, and RevitalVision—examining the science behind each, the evidence supporting their use, and what they mean for the future of amblyopia care. Man Kin (Eric) Chow Miami, Florida Owner, Miami Vision Therapy Fellow, American Academy of Optometry (FAAO) Fellow, Optometric Vision Development & Rehabilitation Association (FOVDR) Clinical Affiliate Faculty/Preceptor, Nova Southeastern University College of Optometry Children’s Vision Committee, Florida Optometric Association
RkJQdWJsaXNoZXIy MjEyMDQ0Nw==